Get notified when SBEV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's going-concern opinion signals the company may not survive without new financing.
- Material Weakness (new) — The company discloses material weaknesses in internal control over financial reporting, which could lead to inaccurate financial statements.
- Nyse American Delisting Risk (new) — The company is out of compliance with NYSE American's stockholders' equity requirement, with negative equity of $15.3 million, and faces delisting if not remedied by January 29, 2027.
- Customer Concentration and Loss (new) — The company's only recent revenue came from a single tequila customer that has terminated its contract, leaving no ongoing beverage revenue.
- Cannepil Sales Decline (new) — Sales of the licensed product CannEpil have collapsed from $4.26 million in 2023 to under $100,000 in 2026, raising doubts about commercial viability.
- Dilution From Convertible Preferred Stock and Warrants (new) — Outstanding preferred stock is convertible into over 11 million common shares, and warrants and options add further potential dilution, significantly reducing existing shareholders' ownership.
Endovia Health Sciences registers resale of 5M shares by selling stockholder; company may receive up to $30.8M from ELOC
Filed August 28, 2026 · ~2 min read
Key Changes
-
high
This is a secondary offering: selling stockholder C/M Capital Master Fund may resell up to 5,000,000 shares; Endovia receives no proceeds from those sales.
The Offering verify on EDGAR → -
high
Endovia may receive up to $30,782,793 in gross proceeds from future sales of shares to C/M under the equity line of credit (ELOC), but the amount is not guaranteed.
Use of Proceeds verify on EDGAR → -
high
The company reported a GAAP net loss of $25.2 million for 2025, including $14.2 million of non-cash items.
Risk Factors verify on EDGAR →
5 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.
Partner
Trade SBEV commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify